New combo aims to deeply suppress leukemia in Early-Stage patients
NCT ID NCT05007873
First seen Jan 10, 2026 · Last updated May 21, 2026 · Updated 24 times
Summary
This study is for people newly diagnosed with a type of leukemia called chronic myeloid leukemia (CML). It tests whether adding a drug called ASTX727 to the standard treatment dasatinib can better control the cancer. About 70 participants will receive the combination and be monitored for side effects and how well the cancer responds. The goal is to see if this approach leads to deeper remission than standard therapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.